These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38762398)

  • 1. Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study.
    Bravo-Marqués R; Becerra-Muñoz V; Espíldora-Hernández F; Recio-Mayoral A;
    Clin Ther; 2024 Jun; 46(6):509-514. PubMed ID: 38762398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension.
    Burger CD; Tang W; Tsang Y; Panjabi S
    JAMA Netw Open; 2024 Sep; 7(9):e2434691. PubMed ID: 39312239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selexipag: A Review in Pulmonary Arterial Hypertension.
    Duggan ST; Keam SJ; Burness CB
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies.
    Chin KM; Channick R; Kim NH; MacDonald G; Ong R; Martin N; Senatore A; McLaughlin VV
    Adv Ther; 2024 Nov; 41(11):4205-4227. PubMed ID: 39316293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
    Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
    J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
    Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
    Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
    Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
    J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study).
    Lange TJ; Escribano-Subias P; Muller A; Fernandes CC; Fontana M; Remenova T; Söderberg S; Gaine S
    Adv Ther; 2024 Sep; 41(9):3645-3663. PubMed ID: 39083197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted therapy of pulmonary arterial hypertension (PAH)].
    Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
    [No Abstract]   [Full Text] [Related]  

  • 16. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry).
    McLaughlin V; Farber HW; Highland KB; Hemnes AR; Chakinala MM; Chin KM; Han M; Cho M; Tobore T; Rahman M; Kim NH
    J Heart Lung Transplant; 2024 Feb; 43(2):272-283. PubMed ID: 37778526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
    Demerouti EA; Karyofyllis P; Apostolopoulou SC
    Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.